Jefferies Cuts Price Target on Anacor Pharma (ANAC) to $105 Following a 4Q EPS Miss

March 1, 2016 9:12 AM

Jefferies maintained a Buy rating on Anacor Pharmaceuticals (NASDAQ: ANAC), and cut the price target to $105.00 (from $159.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found